A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Ceritinib (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 16 Jun 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Feb 2023.
- 16 Jun 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
- 10 Jun 2017 Biomarkers information updated